Publications

We are proud of our progress, excited about our pipeline and eager to uncover our potential through research efforts.

R & D Days

Date Program Title of Publication
Dec 2016 R & D Day

Five Prime R & D Day – December 2016

May 2015 R & D Day

Five Prime R & D Day – May 2015

Cabiralizumab

Date Program Title of Publication
Jun 2018 Cabiralizumab

Pharmacodynamics (PD) and genomic profiling of pts treated with cabiralizumab (cabira) + nivolumab (NIVO) provide evidence of on-target tumor immune modulations and support future clinical applications​ – Abstract

Pharmacodynamics and Genomic Profiling of Patients Treated With Cabiralizumab + Nivolumab Provide Evidence of On-Target Tumor Immune Modulations and Support Future Clinical Application – Poster

American Society of Clinical Oncology (ASCO), June 2018
Carleton M, et al.

Nov 2017 Cabiralizumab

First-in-Human Phase 1 Dose Escalation and Expansion of a Novel Combination, Anti–CSF-1 Receptor (cabiralizumab) Plus Anti–PD-1 (nivolumab), in Patients With Advanced Solid Tumors – Oral Presentation

2017 SITC Late-Breaker Oral Presentation, November 2017
Wainberg Z, et al.

Oct 2017 Cabiralizumab

Tenosynovial Giant Cell Tumor: Incidence, Prevalence, Patient Characteristics, and Recurrence. A Registry-based Cohort Study in Denmark – Journal

The Journal of Rheumatology, October 2017
Ehrenstein, V, Andersen, S, et al.
The Journal of Rheumatology 44  (10)  1476-1483
DOI: 10.3899/jrheum.160816

Jun 2017 Cabiralizumab

A Phase 1/2 Dose Escalation and Expansion Study of Cabiralizumab (FPA008), an anti-CSF1R antibody, in Tenosynovial Giant Cell Tumor (TGCT, Diffuse Pigmented Villonodular Synovitis D-PVNS) – Poster

2017 American Society of Clinical Oncology (ASCO), June 2017
K. Kumar Sankhala et al.

Jun 2017 Cabiralizumab

Cabiralizumab PVNS ASCO 2017 Final Abstract – Abstract

2017 American Society of Clinical Oncology (ASCO), June 2017
Kamalesh S, et al.

Apr 2017 Cabiralizumab

Antibody-Based Inhibition of CSF-1R as a Component of Combination Immunotherapy in Preclinical Models – Poster

American Association for Cancer Research (AACR), April 2017
Bellovin D, et al.

Nov 2015 Cabiralizumab

A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Patients with Rheumatoid Arthritis (RA): Preliminary Results – Poster

A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Subjects with Rheumatoid Arthritis (RA): Preliminary Results – Abstract

American College of Rheumatology (ACR), November 2015
Zhou L, Sikorski R, et al.

Nov 2015 Cabiralizumab

cmFPA008, an Anti-Mouse CSF-1R Antibody, Combines with Multiple Immunotherapies to Reduce Tumor Growth in Nonclinical Models Poster – Poster

cmFPA008, an Anti-Mouse CSF-1R Antibody, Combines with Multiple Immunotherapies to Reduce Tumor Growth in Nonclinical Models – Abstract

Society for Immunotherapy of Cancer (SITC), November 2015
Bellovin D, Wondyfraw N, et al.

Sep 2015 Cabiralizumab

A Phase 1a/1b Study of FPA008 in Combination with Nivolumab in Patients with Selected Advanced Cancers Poster – Poster

A Phase 1a/1b Study of FPA008 in Combination with Nivolumab in Patients with Selected Advanced Cancers – Abstract

CRI-CIMT-EATI-AACR, September 2015
Brahmer J, Rasco D, et al.

Nov 2014 Cabiralizumab

A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Healthy Volunteers and Subjects with Rheumatoid Arthritis (RA): Preliminary Results – Poster

American College of Rheumatology (ACR), November 2014

Sep 2010 Cabiralizumab

Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells – Journal

Journal of Leukocyte Biology, September 2010
Wei S, Nandi S, Chitu V, et al.
J Leukoc Biol
2010;88:495–505.

May 2008 Cabiralizumab

Discovery of a Cytokine and Its Receptor by Functional Screening of the Extracellular Proteome – Journal

Science, May 2008
Lin H, Lee E, et al.
Science 9 May 2008: 807-811
DOI: 10.1126/science.1154370

Bemarituzumab

Date Program Title of Publication
Jun 2018

Bemarituzumab

FIGHT: A phase 3 randomized, double-blind, placebo controlled study evaluating (bemarituzumab) FPA144 and modified FOLFOX6 (mFOLFOX6) in patients with previously untreated advanced gastric and gastroesophageal cancer with a dose finding phase 1 lead-in​ – Abstract

FIGHT: A Phase 3 Randomized, Placebo Controlled Study Evaluating Bemarituzumab (FPA144) and mFOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer – Poster

American Society of Clinical Oncology (ASCO)
Catenacci D, et al.

Nov 2017 Bemarituzumab

FGFR2b expression and baseline immune signature to guide FPA144 development in urothelial cancer – Poster

2017 Society for Immunotherapy of Cancer (SITC)
Lee Y, et al.

Jun 2017 Bemarituzumab

Updated Antitumor Activity and Safety of FPA144, an ADCC-enhanced, FGFR2b Isoform-specific Monoclonal Antibody, in Patients with FGFR2b+ Gastric Cancer – Poster

FPA144 ASCO 2017 Final Abstract – Abstract

2017 American Society of Clinical Oncology (ASCO)
Catenacci, et al.

Dec 2016 Bemarituzumab

FGFR2b Represents a Novel Target for Treatment of Urothelial Cancer – Poster

EORTC-NCI-AACR, December 2016
Ghoddusi M, Pierce K, et al.

Jun  2016 Bemarituzumab

Antitumor Activity and Safety of FPA144, an ADCC enhanced, FGFR2b Isoform-Selective Monoclonal Antibody, in Patients with FGFR2b+ Gastric Cancer and Advanced Solid Tumors – Presentation

American Society of Clinical Oncology (ASCO), June 2016
Lee J, Bendell J, et al.

Apr 2016 Bemarituzumab

FPA144: A Therapeutic Monoclonal Antibody with Enhanced Antibody-Dependent Cell Killing for the Treatment of Fibroblast Growth Factor Receptor 2b Overexpressing Cancers – Presentation

Powers J, Palencia S, et al.

FPA144, a Therapeutic Monoclonal Antibody Targeting the FGFR2b Receptor, Promotes Antibody Dependent Cell-Mediated Cytotoxicity and Stimulates Sensitivity to PD-1 Blockade in the 4T1 Syngeneic Tumor Model in Mice – Poster

FPA144, a Therapeutic Monoclonal Antibody Targeting the FGFR2b Receptor, Promotes Antibody Dependent Cell-Mediated Cytotoxicity and Stimulates Sensitivity to PD-1 the 4T1 Breast Tumor Model in Mice – Abstract

American Association for Cancer Research (AACR), April 2016
Pierce, K.

Jan 2016 Bemarituzumab

FPA144-001: A First in Human Study of FPA144, an ADCC-enhanced, FGFR2b Isoform-selective Monoclonal Antibody in Patients with Advanced Solid Tumors – Poster

ASCO Gastrointestinal Cancers Symposium, January 2016
Bendell J, Rogers S, et al.

Apr 2014 Bemarituzumab

FPA144: A Therapeutic Antibody for Treating Patients with Gastric Cancers Bearing FGFR2 Gene Amplification – Poster

American Association for Cancer Research (AACR), April 2014
Gemo A, Deshpande A, et al.

FPA150

Date Program Title of Publication
Apr 2018 FPA150

FPA150: A First-In-Class T Cell Checkpoint Blocking Antibody with ADCC Activity for the Treatment of Malignancies that Express High Levels of B7-H4 – Presentation

American Association for Cancer Research (AACR), April 2018
Kaplan, Charles et al.

Sep 2017 FPA150

FPA150, a Novel B7-H4 Therapeutic Antibody with Checkpoint Blockade and ADCC Activities – Abstract

FPA150, a Novel B7-H4 Therapeutic Antibody with Checkpoint Blockade and ADCC Activities – Poster

European Society for Medical Oncology (ESMO) 2017 Congress, September 2017
Kaplan, Charles et al.

FPT155

Date Program Title of Publication
Oct 2017 FPT155

FPT155, A Novel Therapeutic CD80-Fc Fusion Protein With Potent Antitumor Activity in Preclinical Models – Poster

American Association for Cancer Research (AACR), October 2017
Barbee S, et al.

IO Research and Preclinical

Date Program Title of Publication
Nov 2015 IO Res & PreCln

Identification of a Novel T Cell Co-Inhibitory Receptor and Potential Therapeutic Antibody Target in Oncology Poster – Poster

Identification of a Novel T Cell Co-Inhibitory Receptor and Potential Therapeutic Antibody Target in Oncology – Abstract

Sallee N, Karasyov A, et al.

Identification of Novel Immune Regulators of Tumor Growth Using RIPPS Screening in vivo Poster – Poster

Identification of Novel Immune Regulators of Tumor Growth Using RIPPS Screening in vivo – Abstract

Brennan T, Bellovin D, et al.

Society for Immunotherapy of Cancer (SITC), November 2015
Sallee N, Karasyov A, et al.

Other Research and Preclinical

Date Program Title of Publication
Apr 2017 Discovery

Identification Of Novel T Cell Co-inhibitory And Co-stimulatory Receptors From Screening A Comprehensive Library Of Extracellular Proteins – Poster

American Association for Cancer Research (AACR), April 2017
Brace A, et al.

May  2015 Discovery

A High Content Screen to Identify Novel Factors That Restore Phagocytosis in COPD Alveolar Macrophages – Poster

American Thoracic Society (ATS), May 2015
Zhu Y, Gosling J, et al.

2015 Discovery

An in vitro Co-culture Model to Characterize Cross-talk between COPD Airway Epithelia and Dendritic Cells – Poster

Keystone Symposium, 2015
Sullivan K, Huang K, et al.

Nov 2014 Discovery

Discovery of Novel Immune Checkpoint Regulators in a Comprehensive Library of Human Extracellular Proteins – Poster

Society for Immunotherapy of Cancer (SITC), November 2014
Sallee N, Lee E, et al.

Sep 2014 Discovery

Deorphanization of the human leukocyte tyrosinekinase (LTK) receptor by a signaling screen of the extracellular proteome – Journal

Proceedings of the National Academy of Sciences (PNAS), September 2014
Zhang H, Pao L, et al.
www.pnas.org/cgi/doi/10.1073/pnas.1412009111

Feb 2009 Discovery

Controlling Feature Selection in Random Forests of Decision Trees Using a Genetic Algorithm: Classification of Class I MHC Peptides. – Journal

Combinatorial Chemistry & High Throughput Screening, February 2009
Hansen L, Lee E, et al.
Combinatorial Chemistry & High Throughput Screening, 2009
Vol. 12, No. 5, 514-519

Aug 2006 Discovery

HTS Technologies in Biopharmaceutical Discovery – Journal

Drug Discovery Today, August 2006
Ge Wu, Stephen K. Doberstein
Volume 11, Issues 15–16, August 2006, Pages 718–724
Drug Discovery Today, 11:15-16.